151 related articles for article (PubMed ID: 23316883)
21. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
[TBL] [Abstract][Full Text] [Related]
22. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
Nitz UA; Gluz O; Christgen M; Grischke EM; Augustin D; Kuemmel S; Braun M; Potenberg J; Kohls A; Krauss K; Stefek A; Schumacher C; Forstbauer H; Reimer T; Fischer H; Liedtke C; Wuerstlein R; Schumacher J; Kates R; Kreipe H; Harbeck N
Ann Oncol; 2017 Nov; 28(11):2768-2772. PubMed ID: 28945833
[TBL] [Abstract][Full Text] [Related]
23. Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
Castagnoli L; Iorio E; Dugo M; Koschorke A; Faraci S; Canese R; Casalini P; Nanni P; Vernieri C; Di Nicola M; Morelli D; Tagliabue E; Pupa SM
J Cell Physiol; 2019 Feb; 234(2):1768-1779. PubMed ID: 30132876
[TBL] [Abstract][Full Text] [Related]
24. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer.
Kim MM; Dawood S; Allen P; Sahin AA; Woodward WA; Smith BD; Strom EA; Hunt KK; Meric-Bernstam F; Gonzalez-Angulo AM; Buchholz TA
Cancer; 2012 Oct; 118(20):4936-43. PubMed ID: 22511276
[TBL] [Abstract][Full Text] [Related]
25. Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.
Cheng H; Bai Y; Sikov W; Sinclair N; Bossuyt V; Abu-Khalaf MM; Harris LN; Rimm DL
BMC Cancer; 2014 May; 14():326. PubMed ID: 24885187
[TBL] [Abstract][Full Text] [Related]
26. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Bon G; Pizzuti L; Laquintana V; Loria R; Porru M; Marchiò C; Krasniqi E; Barba M; Maugeri-Saccà M; Gamucci T; Berardi R; Livi L; Ficorella C; Natoli C; Cortesi E; Generali D; La Verde N; Cassano A; Bria E; Moscetti L; Michelotti A; Adamo V; Zamagni C; Tonini G; Barchiesi G; Mazzotta M; Marinelli D; Tomao S; Marchetti P; Valerio MR; Mirabelli R; Russo A; Fabbri MA; D'Ostilio N; Veltri E; Corsi D; Garrone O; Paris I; Sarobba G; Giotta F; Garufi C; Cazzaniga M; Del Medico P; Roselli M; Sanguineti G; Sperduti I; Sapino A; De Maria R; Leonetti C; Di Leo A; Ciliberto G; Falcioni R; Vici P
J Exp Clin Cancer Res; 2020 Dec; 39(1):279. PubMed ID: 33302999
[TBL] [Abstract][Full Text] [Related]
27. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
Loi S; Michiels S; Lambrechts D; Fumagalli D; Claes B; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Piccart MJ; Joensuu H; Sotiriou C
J Natl Cancer Inst; 2013 Jul; 105(13):960-7. PubMed ID: 23739063
[TBL] [Abstract][Full Text] [Related]
28. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.
Nam S; Chang HR; Jung HR; Gim Y; Kim NY; Grailhe R; Seo HR; Park HS; Balch C; Lee J; Park I; Jung SY; Jeong KC; Powis G; Liang H; Lee ES; Ro J; Kim YH
Cancer Lett; 2015 Jan; 356(2 Pt B):880-90. PubMed ID: 25449779
[TBL] [Abstract][Full Text] [Related]
29. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
[TBL] [Abstract][Full Text] [Related]
30. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
31. Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.
Horii R; Nitta H; Nojima M; Maruyama R; Ueno T; Ito Y; Ohno S; Banks P; Kanda H; Akiyama F
Virchows Arch; 2021 Jul; 479(1):13-21. PubMed ID: 33496805
[TBL] [Abstract][Full Text] [Related]
32. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Veeraraghavan J; De Angelis C; Mao R; Wang T; Herrera S; Pavlick AC; Contreras A; Nuciforo P; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Wolff AC; Krop IE; Fuqua SAW; Prat A; Hilsenbeck SG; Weigelt B; Reis-Filho JS; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
Ann Oncol; 2019 Jun; 30(6):927-933. PubMed ID: 30903140
[TBL] [Abstract][Full Text] [Related]
33. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
34. Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.
Bhargava R; Dabbs DJ; Beriwal S; Yildiz IA; Badve P; Soran A; Johnson RR; Brufsky AM; Lembersky BC; McGuire KP; Ahrendt GM
Mod Pathol; 2011 Mar; 24(3):367-74. PubMed ID: 21102420
[TBL] [Abstract][Full Text] [Related]
35. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
36. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
37. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
38. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
39. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
Swain SM; Kim SB; Cortés J; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Knott A; Clark E; Ross G; Benyunes MC; Baselga J
Lancet Oncol; 2013 May; 14(6):461-71. PubMed ID: 23602601
[TBL] [Abstract][Full Text] [Related]
40. Correlation Between Preoperative Radiological and Postoperative Pathological Tumor Size in Patients With HER2
Falcone V; Reiser E; Grula L; Bago-Horvath Z; Stolz M; Catic A; Deutschmann C; Singer C; Pfeiler G
Clin Breast Cancer; 2022 Feb; 22(2):149-160. PubMed ID: 34229944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
